TriangleBRiTE (NCT04903795)
BRiTE trial for Newly Diagnosed Glioblastoma (NCT04903795). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Immune therapies that work elsewhere have failed in glioblastoma, partly because so few T cells ever reach the tumor.
The idea: a molecule that grabs a T cell with one hand and a tumor cell with the other.
A third of glioblastomas carry EGFRvIII, a mutant receptor found only on tumor cells. At Duke, a bispecific T cell engager binds EGFRvIII on one arm and CD3 on T cells with the other, forcing the two together so the T cell kills. Because the molecule clears quickly, it is infused continuously for four days in each four-week cycle.
BRiTE is a first dose-finding study in adults whose tumors test positive, newly diagnosed or recurrent. The Duke BRiTE team runs it. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.